The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus
Open accessAbstract
Staphylococcus aureus is the causative agent of several serious infectious diseases. The emergence of antibiotic-resistant S. aureus strains has resulted in significant treatment difficulties, intensifying the need for new antimicrobial agents. Toward this end, we have developed a novel chimeric bacteriophage (phage) lysin that is active against staphylococci, including methicillin-resistant S. aureus (MRSA). The chimeric lysin (called ClyS) was obtained by fusing the N-terminal catalytic domain of the S. aureus Twort phage lysin with the C-terminal cell wall-targeting domain from another S. aureus phage lysin (phiNM3), which displayed Staphylococcus -specific binding. ClyS was expressed in Escherichia coli , and the purified protein lysed MRSA, vancomycin-intermediate strains of S. aureus (VISA), and methicillin-sensitive (MSSA) strains of S. aureus in vitro . In a mouse nasal decolonization model, a 2-log reduction in the viability of MRSA cells was seen 1 h following a single treatment with ClyS. One intraperitoneal dose of ClyS also protected against death by MRSA in a mouse septicemia model. ClyS showed a typical pattern of synergistic interactions with both vancomycin and oxacillin in vitro . More importantly, ClyS and oxacillin at doses that were not protective individually protected synergistically against MRSA septic death in a mouse model. These results strongly support the development of ClyS as an attractive addition to the current treatment options of multidrug-resistant S. aureus infections and would allow for the reinstatement of antibiotics shelved because of mounting resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rajendran, P. M., Young, D., Maurer, T., Chambers, H., Perdreau-Remington, F., Ro, P., & Harris, H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00377-07 · Cited by 214
Cited by
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 998
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Composition and functions of bacterial membrane vesicles
Toyofuku, M., Schild, S., Kaparakis-Liaskos, M., & Eberl, L. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00875-5 · Cited by 597
Nelson, D. C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D. G., Dong, S., & Donovan, D. M. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00007-4 · Cited by 372
Prophage-triggered membrane vesicle formation through peptidoglycan damage in Bacillus subtilis
Toyofuku, M., Cárcamo-Oyarce, G., Yamamoto, T., Eisenstein, F., Hsiao, C.-C., Kurosawa, M., Gademann, K., Pilhofer, M., Nomura, N., & Eberl, L. (2017) · Nature Communications · doi:10.1038/s41467-017-00492-w · Cited by 330
Metadata
- Authors
- Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J., & Fischetti, V. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-04
- Volume
- 54
- Issue
- 4
- Pages
- 1603-1612
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2109861005
- Cited by
- 233
- References
- 1
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus. https://app.cochat.ai/papers/10.1128/aac.01625-09
- The paper
- Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J., & Fischetti, V. A. (2010). Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01625-09
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.